Form D · Pharmaceuticals
Liminatus Pharma, Inc.
Fullerton, CA · CIK 0001971387
Offering snapshot reported Jun 18, 2026 · SEC filing
- Reported sold
- $1.86M Offering amount: $1.86M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 3, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 18, 2026 | Initial | $1,861,920 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $149K
- Finders' fees
- $0
- Form D file number
- 021-587962
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Maxim Group LLC | 000120708 |
Source: Form D, filed Jun 18, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ji Yeon Baek | Director |
| Beom K. Choi | Executive |
| Scott Dam | Executive |
| Nicholas Fernandez | Director |
| Chris Kim | Director, Executive |
| Sang Jin Daniel Lee | Executive |
| Eun Sook Lee | Director |
| Byong C. Yoo | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2251 Stern Goodman Street, Suite E
Fullerton, CA, 92833
Phone: 213-273-5453
Fullerton, CA, 92833
Phone: 213-273-5453